Does the media prefer RYTM or URGN?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.94 beat Rhythm Pharmaceuticals' score of 0.79 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to URGN or MIRM?

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.94 beat Mirum Pharmaceuticals' score of 0.88 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, URGN or LNTH?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 18.18 -$153.49M -$2.75 N/A Lantheus $1.54B 4.43 $233.56M $4.15 25.26

Is URGN or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Urogen Pharma's net margin of -94.83%. Lantheus' return on equity of 29.32% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Urogen Pharma -94.83% N/A -62.85% Lantheus 18.05% 29.32% 15.00%

Does the media favor URGN or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Urogen Pharma. Lantheus' average media sentiment score of 1.35 beat Urogen Pharma's score of 0.94 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor URGN or COGT?

In the previous week, Cogent Biosciences had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Cogent Biosciences and 3 mentions for Urogen Pharma. Cogent Biosciences' average media sentiment score of 1.71 beat Urogen Pharma's score of 0.94 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to URGN or XENE?

In the previous week, Xenon Pharmaceuticals had 7 more articles in the media than Urogen Pharma. MarketBeat recorded 10 mentions for Xenon Pharmaceuticals and 3 mentions for Urogen Pharma. Xenon Pharmaceuticals' average media sentiment score of 1.40 beat Urogen Pharma's score of 0.94 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Urogen Pharma (URGN) Competitors

$40.97 -1.53 (-3.60%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$41.20 +0.23 (+0.56%)

As of 07/24/2026 07:34 PM Eastern

Compare

URGN vs. RYTM, MIRM, LNTH, COGT, and XENE

Should you buy Urogen Pharma stock or one of its competitors? MarketBeat compares Urogen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Urogen Pharma include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Cogent Biosciences (COGT), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Urogen Pharma compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Urogen Pharma (NASDAQ:URGN) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Urogen Pharma has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	36.87	-$196.54M	-$3.13	N/A
Urogen Pharma	$109.79M	18.18	-$153.49M	-$2.75	N/A

Rhythm Pharmaceuticals currently has a consensus target price of $138.29, indicating a potential upside of 35.44%. Urogen Pharma has a consensus target price of $41.63, indicating a potential upside of 1.60%. Given Rhythm Pharmaceuticals' higher possible upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Urogen Pharma. MarketBeat recorded 8 mentions for Rhythm Pharmaceuticals and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.94 beat Rhythm Pharmaceuticals' score of 0.79 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Urogen Pharma	-94.83%	N/A	-62.85%

91.3% of Urogen Pharma shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Rhythm Pharmaceuticals beats Urogen Pharma on 9 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to Mirum Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Mirum Pharmaceuticals has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	18.18	-$153.49M	-$2.75	N/A
Mirum Pharmaceuticals	$569.61M	12.10	-$23.36M	-$13.61	N/A

Urogen Pharma has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

91.3% of Urogen Pharma shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Urogen Pharma presently has a consensus price target of $41.63, indicating a potential upside of 1.60%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 26.87%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Mirum Pharmaceuticals had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Mirum Pharmaceuticals and 3 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.94 beat Mirum Pharmaceuticals' score of 0.88 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Urogen Pharma has a net margin of -94.83% compared to Mirum Pharmaceuticals' net margin of -140.24%. Urogen Pharma's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Urogen Pharma on 9 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Lantheus?

Urogen Pharma (NASDAQ:URGN) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	18.18	-$153.49M	-$2.75	N/A
Lantheus	$1.54B	4.43	$233.56M	$4.15	25.26

Urogen Pharma presently has a consensus price target of $41.63, indicating a potential upside of 1.60%. Lantheus has a consensus price target of $110.43, indicating a potential upside of 5.35%. Given Lantheus' higher possible upside, analysts clearly believe Lantheus is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Urogen Pharma has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lantheus had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Urogen Pharma. Lantheus' average media sentiment score of 1.35 beat Urogen Pharma's score of 0.94 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Urogen Pharma's net margin of -94.83%. Lantheus' return on equity of 29.32% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Lantheus	18.05%	29.32%	15.00%

Summary

Lantheus beats Urogen Pharma on 12 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to Cogent Biosciences?

Urogen Pharma (NASDAQ:URGN) and Cogent Biosciences (NASDAQ:COGT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Cogent Biosciences has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Cogent Biosciences	N/A	-104.27%	-54.64%

Urogen Pharma presently has a consensus price target of $41.63, suggesting a potential upside of 1.60%. Cogent Biosciences has a consensus price target of $45.90, suggesting a potential upside of 15.44%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Cogent Biosciences is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

91.3% of Urogen Pharma shares are held by institutional investors. 4.8% of Urogen Pharma shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Urogen Pharma has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Urogen Pharma has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	18.18	-$153.49M	-$2.75	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

In the previous week, Cogent Biosciences had 1 more articles in the media than Urogen Pharma. MarketBeat recorded 4 mentions for Cogent Biosciences and 3 mentions for Urogen Pharma. Cogent Biosciences' average media sentiment score of 1.71 beat Urogen Pharma's score of 0.94 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Cogent Biosciences beats Urogen Pharma on 10 of the 16 factors compared between the two stocks.

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Xenon Pharmaceuticals (NASDAQ:XENE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Urogen Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Urogen Pharma has higher revenue and earnings than Xenon Pharmaceuticals. Urogen Pharma is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	18.18	-$153.49M	-$2.75	N/A
Xenon Pharmaceuticals	$7.50M	843.22	-$345.91M	-$4.70	N/A

Urogen Pharma currently has a consensus target price of $41.63, indicating a potential upside of 1.60%. Xenon Pharmaceuticals has a consensus target price of $77.20, indicating a potential upside of 18.01%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Xenon Pharmaceuticals had 7 more articles in the media than Urogen Pharma. MarketBeat recorded 10 mentions for Xenon Pharmaceuticals and 3 mentions for Urogen Pharma. Xenon Pharmaceuticals' average media sentiment score of 1.40 beat Urogen Pharma's score of 0.94 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xenon Pharmaceuticals beats Urogen Pharma on 11 of the 17 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.07B	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-14.90	21.11	27.00	23.71
Price / Sales	18.18	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-18.21	7.88	10.28	6.07
Net Income	-$153.49M	$23.81M	$3.60B	$331.99M
7 Day Performance	1.84%	-3.82%	-1.29%	-0.61%
1 Month Performance	19.17%	-2.61%	-0.38%	-1.98%
1 Year Performance	116.20%	32.79%	18.32%	13.67%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	1.96 of 5 stars	$40.97 -3.6%	$41.63 +1.6%	+127.6%	$2.07B	$109.79M	N/A	200	Analyst Forecast
RYTM Rhythm Pharmaceuticals	2.9798 of 5 stars	$109.69 -0.2%	$138.29 +26.1%	+17.0%	$7.54B	$189.76M	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	2.8946 of 5 stars	$121.00 +0.1%	$143.40 +18.5%	+116.7%	$7.37B	$521.31M	N/A	140	Upcoming Earnings
LNTH Lantheus	3.3187 of 5 stars	$104.32 +1.9%	$109.00 +4.5%	+47.8%	$6.66B	$1.54B	25.14	1,193	News Coverage
COGT Cogent Biosciences	1.7986 of 5 stars	$39.30 +2.1%	$43.73 +11.3%	+226.2%	$6.58B	N/A	N/A	80	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. RYTM, MIRM, LNTH, COGT, and XENE

How does Urogen Pharma compare to Rhythm Pharmaceuticals?

Summary

How does Urogen Pharma compare to Mirum Pharmaceuticals?

Summary

How does Urogen Pharma compare to Lantheus?

Summary

How does Urogen Pharma compare to Cogent Biosciences?

Summary

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. RYTM, MIRM, LNTH, COGT, and XENE

How does Urogen Pharma compare to Rhythm Pharmaceuticals?

Which has stronger earnings and valuation, RYTM or URGN?

Do analysts rate RYTM or URGN?

Which has more risk & volatility, RYTM or URGN?

Does the media prefer RYTM or URGN?

Is RYTM or URGN more profitable?

Do institutionals & insiders believe in RYTM or URGN?

Summary

How does Urogen Pharma compare to Mirum Pharmaceuticals?

Which has better valuation and earnings, URGN or MIRM?

Which has more volatility and risk, URGN or MIRM?

Do insiders and institutionals hold more shares of URGN or MIRM?

Do analysts rate URGN or MIRM?

Does the media refer more to URGN or MIRM?

Is URGN or MIRM more profitable?

Summary

How does Urogen Pharma compare to Lantheus?

Which has higher valuation and earnings, URGN or LNTH?

Do analysts prefer URGN or LNTH?

Which has more risk & volatility, URGN or LNTH?

Do institutionals and insiders hold more shares of URGN or LNTH?

Does the media favor URGN or LNTH?

Is URGN or LNTH more profitable?

Summary

How does Urogen Pharma compare to Cogent Biosciences?

Is URGN or COGT more profitable?

Do analysts recommend URGN or COGT?

Do institutionals and insiders hold more shares of URGN or COGT?

Which has more volatility & risk, URGN or COGT?

Which has stronger valuation and earnings, URGN or COGT?

Does the media favor URGN or COGT?

Summary

How does Urogen Pharma compare to Xenon Pharmaceuticals?

Which has more volatility & risk, URGN or XENE?

Is URGN or XENE more profitable?

Do institutionals and insiders believe in URGN or XENE?

Which has higher earnings & valuation, URGN or XENE?

Do analysts recommend URGN or XENE?

Does the media refer more to URGN or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools